Please assess the completion status of the following clinical trial:

Trial Title: Biomarkers in Giant Cells Arteritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient suffering from giant cells arteritis.~* Inclusion while discovery of symptoms, or during relapse.~Exclusion Criteria:~* Healthy volunteer~* Treatment with corticosteroid since more than 8 days for a patient suffering from giant cells arteritis, exept for patients under corticosteroid for a polymyalgia rheumatica.~* Other diseases than giant cells arteritis that could introduce an inflammatory symptom, especially a tumoral process in progress or a chronic inflammatory disease (any other one than giant cells arteritis)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient with giant gells arteritis (Type: OTHER): 50 patients with giant gells arteritis
- Control patients (Type: OTHER): 50 control patients : blood from French national blood service (EFS)

Based on this trial design, predict the completion outcome and termination type (if applicable).